Back to top

oncology-screening: Archive

Zacks Equity Research

EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line

Exelixis' first-quarter earnings and sales beat estimates as lead drug Cabometyx maintains momentum. The company raises its sales guidance for 2025.

BAYRYPositive Net Change EXELNegative Net Change EDITPositive Net Change ALLOPositive Net Change

Shaun Pruitt

Buy Stock in These Healthcare Leaders as Q1 Earnings Approach? ABBV, HCA

The medical sector can provide a defensive hedge against economic uncertainty, and investors may be eyeing AbbVie (ABBV) and HCA Healthcare (HCA) stock ahead of their Q1 reports on Friday, April 25.

HCANegative Net Change ABBVNegative Net Change

Zacks Equity Research

MURA Soars as it Explores Strategic Options Post Cancer Study Failures

Mural Oncology stock skyrockets after it begins exploring strategic alternatives to maximize shareholder value after the failure of two cancer studies for nemvaleukin alfa.

DVAXPositive Net Change BAYRYPositive Net Change ADMAPositive Net Change MURAPositive Net Change

Urmimala Biswas

Tap Into the Silver Economy Boom With These Aging Demographics Stocks

The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.

ABTNegative Net Change NVOPositive Net Change RMDNegative Net Change DXCMPositive Net Change EXASPositive Net Change TNDMPositive Net Change

Zacks Equity Research

PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose

Phio Pharmaceuticals stock rallies as safety committee gives green light to advance skin cancer candidate to next dose concentration in phase I study.

DVAXPositive Net Change BAYRYPositive Net Change ADMAPositive Net Change PHIONo Net Change